| | | | | | | |
 | GILEAD SCIENCES, INC. | -0.14% | 4.39% | -13.06% | -7.84% | -4.15% | 79 298 |
| REGENERON PHARMACEUTICALS, INC. | -0.64% | 7.53% | 3.71% | 28.36% | 116.47% | 71 026 |
| VERTEX PHARMACEUTICALS | 0.92% | 7.40% | 15.97% | 18.98% | 53.67% | 64 540 |
 | WUXI APPTEC CO., LTD. | -0.43% | -4.94% | -19.12% | -28.55% | 180.36% | 41 409 |
| BIONTECH SE | 7.71% | 8.95% | -34.38% | -15.02% | --.--% | 38 169 |
 | GENMAB A/S | 0.33% | 3.20% | -18.90% | -7.06% | 84.84% | 19 651 |
 | ARGENX SE | 2.08% | 4.98% | -5.17% | 35.17% | 162.05% | 16 793 |
| BEIGENE, LTD. | -0.43% | 8.24% | -51.82% | -60.98% | 5.41% | 13 526 |
| NEUROCRINE BIOSCIENCES, INC. | 0.50% | 3.72% | 0.24% | -7.55% | 11.34% | 8 119 |
| LEGEND BIOTECH CORPORATION | 2.34% | 19.61% | -10.68% | 15.83% | --.--% | 6 274 |
| EXELIXIS, INC. | -9.54% | -1.76% | -3.56% | -25.30% | -10.10% | 6 251 |
| SAREPTA THERAPEUTICS, INC. | 1.51% | 9.19% | -22.82% | -9.64% | -40.88% | 5 991 |
| HALOZYME THERAPEUTICS, INC. | 1.77% | 16.39% | 8.83% | 4.02% | 187.33% | 5 924 |
| INTRA-CELLULAR THERAPIES, INC. | 2.42% | 9.59% | 14.47% | 57.34% | 387.50% | 5 518 |
 | BIOCON LIMITED | -4.54% | 1.08% | -11.56% | -16.23% | 23.86% | 5 170 |
| | | | | | | |
| | Moyenne | 0.26% | 6.50% | -9.86% | -1.23% | 89.05% | |
| | Moyenne pondérée par Capi. | 0.73% | 5.44% | -8.14% | 1.46% | 77.19% | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
bourse
Rapport
